Cellectis (CLLS) Profit After Tax Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 33.04% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 30.60% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -154.28% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 13.80% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 16.53% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -3.84% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 47.10% |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | 18.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.09% |
| Dec 31, 2025 | 2.69% |
| Sep 30, 2025 | -9.70% |
| Jun 30, 2025 | 22.43% |
| Mar 31, 2025 | 17.18% |
| Dec 31, 2024 | 30.27% |
| Sep 30, 2024 | 36.30% |
| Jun 30, 2024 | 27.63% |
| Mar 31, 2024 | 33.28% |
| Dec 31, 2023 | -45.40% |
| Sep 30, 2023 | 19.57% |
| Jun 30, 2023 | -10.84% |
| Mar 31, 2023 | -56.21% |
| Dec 31, 2022 | 11.47% |
| Sep 30, 2022 | -17.07% |
| Jun 30, 2022 | -11.55% |
| Mar 31, 2022 | -27.91% |
| Dec 31, 2021 | -2.51% |
| Sep 30, 2021 | -52.17% |
| Jun 30, 2021 | -74.55% |
| Mar 31, 2021 | 17.20% |
| Dec 31, 2020 | 53.64% |
| Sep 30, 2020 | 22.53% |
| Jun 30, 2020 | 22.74% |
| Mar 31, 2020 | 41.61% |
| Dec 31, 2019 | -45.18% |
| Sep 30, 2019 | -11.50% |
| Jun 30, 2019 | -73.07% |
| Mar 31, 2019 | 22.30% |
| Dec 31, 2018 | -69.68% |
| Sep 30, 2018 | -21.25% |
| Jun 30, 2018 | 26.47% |
| Mar 31, 2018 | -79.56% |
| Dec 31, 2017 | -947.99% |